基于体外数据的PBPK模型前瞻性评估Vicasinabin的药物相互作用风险
Vicasinabin是口服CB2激动剂,主要经CYP3A4代谢,体外显示诱导CYP3A4并抑制肝/肾转运体。研究采用自下而上PBPK模型预测其作为受害药和 perpetrator 的DDI风险,预测结果与临床DDI研究数据一致,并模拟了CYP3A4/CYP2C19抑制剂及利福平的影响。
要点
- PBPK模型预测Vicasinabin使咪达唑仑全身暴露中度降低。
- 模型预测对阿托伐他汀和二甲双胍的转运体抑制无临床相关性,经临床DDI数据证实。
- CYP2C19基因型因fm约0.2对Vicasinabin作为受害药的DDI预测无显著影响。
核心结论
- 基于体外数据的PBPK模型可前瞻性预测Vicasinabin的临床DDI风险。
- CYP2C19基因型对Vicasinabin作为受害药的DDI预测无显著影响。
研究设计与样本
- 研究采用自下而上方法构建Vicasinabin的PBPK模型,整合体外代谢与转运体数据。
- 模型预测结果与临床DDI研究数据进行了比较验证。
主要发现
- PBPK模型预测Vicasinabin使选择性CYP3A4底物咪达唑仑的全身暴露中度降低。
- 模型预测Vicasinabin对OATP1B1/P-gp/CYP3A4介导的阿托伐他汀处置及OCT2/MATE1介导的二甲双胍处置无临床相关性,临床DDI数据证实。
- 使用体外fm,CYP3A4为0.6成功预测伊曲康唑DDI后,模型模拟了红霉素、氟康唑、氟伏沙明、依非韦伦和利福平合用后Vicasinabin的弱或中度暴露变化。
- 模型还提示利福平诱导可对Vicasinabin产生强效应。
- CYP2C19基因型因fm,CYP2C19约0.2对Vicasinabin作为受害药的DDI预测无显著影响。
临床怎么用
- 临床药师可利用PBPK模型前瞻性评估Vicasinabin与CYP3A4/CYP2C19调节药物合用的DDI风险。
- 关注Vicasinabin与强CYP3A4诱导剂利福平合用的潜在强诱导效应。
- CYP2C19基因型检测对Vicasinabin的DDI风险评估价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vicasinabin is an oral cannabinoid receptor 2 (CB2) agonist showing anti-inflammatory effects and was developed for the treatment of chronic inflammatory diseases such as diabetic retinopathy. Vicasinabin is mainly metabolized by CYP3A4, with minor contributions from CYP2C19 and UGTs. The drug shows in vitro induction of CYP3A4, as well as inhibition of hepatic and renal transporters. Translation of in vitro data to a clinical drug-drug interaction (DDI) risk assessment has been challenging, with a potential role of CYP2C19 genotypes in the pharmacokinetics to be considered. A physiologically based pharmacokinetic (PBPK) model of vicasinabin based on a bottom-up approach predicted a moderate systemic exposure reduction for the selective CYP3A4 substrate midazolam. Neither the OATP1B1/P-gp/CYP3A4 inhibition effect on atorvastatin nor the OCT2/MATE1 inhibition effect on metformin was predicted to be of clinical relevance by PBPK modeling, as was confirmed by clinical DDI study data. After successful PBPK model prediction of itraconazole DDI using an in vitro fm,CYP3A4 of 0.6, the model was applied to simulate weak or moderate exposure changes of vicasinabin after co-administration with perpetrators for CYP3A4 and CYP2C19 (erythromycin, fluconazole, fluvoxamine, efavirenz, and rifampicin). A strong effect of induction due to rifampicin was also indicated. The CYP2C19 genotypes did not result in a significant impact on the victim DDI prediction for vicasinabin due to a low fm,CYP2C19 (∼0.2). The case study illustrated the usefulness of prospective PBPK predictions of clinical drug-drug interactions using in vitro data.
引用
- Umehara K, Parrott N, Günther A, et al. Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data. Clin Pharmacol Ther. 2025. PMID: 40294080. doi:10.1002/cpt.3686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。